The present invention relates to azole bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
The present disclosure relates to compounds useful as inhibitors of the enzyme Fatty Acid Amide Hydrolase (FAAH). The disclosure also provides pharmaceutically acceptable compositions comprising the compounds of the disclosure and methods of using the compositions in the treatment or prevention of various disorders. Compounds of the invention are described in Table 1.
Overcoming Selectivity Issues in Reversible Catalysis: A Transfer Hydrocyanation Exhibiting High Kinetic Control
作者:Benjamin N. Bhawal、Julia C. Reisenbauer、Christian Ehinger、Bill Morandi
DOI:10.1021/jacs.0c03184
日期:2020.6.24
Reversible catalytic reactions operate under thermodynamic control and thus establishing a selective catalytic system poses a considerable challenge. Herein, we report a reversible transfer hydrocyanation protocol that exhibits high selectivity for the thermodynamically less favorable branched isomer. Selectivity is achieved by exploiting the lower barrier for C-CN oxidative addition and reductive elimination
[EN] NEW FLUORESCENT DYES AND THEIR USES AS BIOMARKERS<br/>[FR] NOUVEAUX COLORANTS FLUORESCENTS ET LEURS UTILISATIONS EN TANT QUE BIOMARQUEURS
申请人:ILLUMINA CAMBRIDGE LTD
公开号:WO2018060482A1
公开(公告)日:2018-04-05
The present application relates to new fluorescent dyes and their uses as fluorescent labels. The compounds may be used as fluorescent labels for nucleotides in nucleic acid sequencing applications.
本申请涉及新的荧光染料及其作为荧光标记物的用途。这些化合物可用作核酸测序应用中核苷酸的荧光标记物。
COMPOUNDS FOR THE TREATMENT OF ADDICTION
申请人:Cannizzaro Carina E.
公开号:US20130005689A1
公开(公告)日:2013-01-03
Disclosed are novel compounds having the structure of Formula (I):
which are useful for treating mammals for dependence upon substances of addiction, for example addiction to a dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and/or alcohol. Also disclosed are pharmaceutical compositions comprising a therapeutically effective amount of a compound of Formula (I) and methods of using the compounds of Formula (I) in the treatment of addiction to a dopamine-producing agent.